JP2018131439A - Ｈｃｖを処置する方法 - Google Patents

Ｈｃｖを処置する方法 Download PDF

Info

Publication number
JP2018131439A
JP2018131439A JP2018021874A JP2018021874A JP2018131439A JP 2018131439 A JP2018131439 A JP 2018131439A JP 2018021874 A JP2018021874 A JP 2018021874A JP 2018021874 A JP2018021874 A JP 2018021874A JP 2018131439 A JP2018131439 A JP 2018131439A
Authority
JP
Japan
Prior art keywords
weeks
hcv
compound
patient
daas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018021874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018131439A5 (enExample
Inventor
ワリード・エム・アウニ
M Awni Walid
バリー・エム・バーンスタイン
M Bernstein Barry
アンドリュー・エル・キャンベル
L Campbell Andrew
サンディープ・ダッタ
Sandeep Dutta
チー−ウェイ・リン
Chih-Wei Lin
ウェイ・リウ
Wei Liu
ラジーブ・エム・メノン
M Menon Rajeev
スフェン・メンシング
Mensing Sven
トーマス・ジェイ・ポトサデツキ
J Podsadecki Thomas
ティアンリ・ワン
Tianli Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/431,906 external-priority patent/US11484534B2/en
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2018131439A publication Critical patent/JP2018131439A/ja
Publication of JP2018131439A5 publication Critical patent/JP2018131439A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018021874A 2017-02-14 2018-02-09 Ｈｃｖを処置する方法 Pending JP2018131439A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/431,906 US11484534B2 (en) 2013-03-14 2017-02-14 Methods for treating HCV
US15/431,906 2017-02-14

Publications (2)

Publication Number Publication Date
JP2018131439A true JP2018131439A (ja) 2018-08-23
JP2018131439A5 JP2018131439A5 (enExample) 2021-04-01

Family

ID=61192811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018021874A Pending JP2018131439A (ja) 2017-02-14 2018-02-09 Ｈｃｖを処置する方法

Country Status (7)

Country Link
EP (1) EP3360555A1 (enExample)
JP (1) JP2018131439A (enExample)
CN (1) CN108421029A (enExample)
AU (1) AU2018201011A1 (enExample)
BR (1) BR102018002956A2 (enExample)
CA (1) CA2994496A1 (enExample)
MX (1) MX2018001905A (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513695A (ja) * 2013-03-14 2016-05-16 アッヴィ・インコーポレイテッド Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用
WO2017007934A1 (en) * 2015-07-08 2017-01-12 Abbvie Inc. Methods for treating hcv

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1742913A1 (en) * 2003-12-11 2007-01-17 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
DK2618831T3 (en) 2010-09-21 2016-04-04 Enanta Pharm Inc Macrocyclic prolinafledte HCV serine protease inhibitors
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
DE202012012956U1 (de) * 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
WO2014152635A1 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
BR112016022976A8 (pt) * 2014-04-02 2021-07-20 Abbvie Inc métodos para o tratamento de hcv

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513695A (ja) * 2013-03-14 2016-05-16 アッヴィ・インコーポレイテッド Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用
WO2017007934A1 (en) * 2015-07-08 2017-01-12 Abbvie Inc. Methods for treating hcv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, 2016, VOL.151, NO.4, PP.651-659, JPN6021046874, ISSN: 0004833388 *
HEPATOLOGY, 2016.10, vol. Vol.64, No.1, suppl.1, JPN6021046872, pages 132 - 133, ISSN: 0004833387 *
STUDY NCT02604017 ON DATE: JANUARY 31, 2017 (V7)，CLINICALTRIALS.GOV ARCHIVE[ONLINE]，2017年1月31日, JPN6021046875, ISSN: 0004649016 *

Also Published As

Publication number Publication date
CN108421029A (zh) 2018-08-21
EP3360555A1 (en) 2018-08-15
BR102018002956A2 (pt) 2018-10-30
CA2994496A1 (en) 2018-08-14
AU2018201011A1 (en) 2018-08-30
MX2018001905A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
JP2021130720A (ja) Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用
AU2014239322B2 (en) Combination of direct acting antiviral agents and ribavirin for treating HCV patients
US20240232171A1 (en) Methods for Treating HCV
JP2017509670A (ja) Ｈｃｖを処置するための方法
JP2019214578A (ja) Ｈｃｖを処置するための方法
US20170360783A1 (en) Methods for Treating HCV
US20170333428A1 (en) Methods for Treating HCV
US11484534B2 (en) Methods for treating HCV
US20240082245A1 (en) Methods for Treating HCV
US20250057837A1 (en) Methods for Treating HCV
JP2018131439A (ja) Ｈｃｖを処置する方法
JP2019026633A (ja) Ｈｃｖを処置する方法
HK1259694A1 (en) Methods for treating hcv
US20200330460A1 (en) Methods for Treating HCV
HK40004326A (en) Methods for treating hcv
JP2020536909A (ja) Ｈｃｖを処置するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726